According to Curis's latest financial reports the company's current revenue (TTM) is $10.02 M. In 2022 the company made a revenue of $10.16 M a decrease over the years 2021 revenue that were of $10.64 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $10.02 M | -1.37% |
2022 | $10.16 M | -4.57% |
2021 | $10.64 M | -1.72% |
2020 | $10.83 M | 8.31% |
2019 | $10 M | -4.07% |
2018 | $10.42 M | 5.35% |
2017 | $9.89 M | 31.5% |
2016 | $7.52 M | -4.47% |
2015 | $7.87 M | -19.96% |
2014 | $9.84 M | -34.39% |
2013 | $15 M | -11.61% |
2012 | $16.97 M | 14.97% |
2011 | $14.76 M | -7.73% |
2010 | $15.99 M | 86.26% |
2009 | $8.58 M | 2.67% |
2008 | $8.36 M | -48.95% |
2007 | $16.38 M | 9.73% |
2006 | $14.93 M | 31.12% |
2005 | $11.39 M | 129.99% |
2004 | $4.95 M | -55.17% |
2003 | $11.04 M | -39.92% |
2002 | $18.39 M | 1592.63% |
2001 | $1.08 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Pfizer PFE | $58.49 B | 583,527.66% | ๐บ๐ธ USA |
Bristol-Myers Squibb BMY | $45.00 B | 448,927.24% | ๐บ๐ธ USA |
Spectrum Pharmaceuticals
SPPI | $25.72 M | 156.70% | ๐บ๐ธ USA |
Exelixis EXEL | $1.83 B | 18,160.08% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $6.88 M | -31.33% | ๐บ๐ธ USA |
Cel-Sci
CVM | N/A | N/A | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $1.02 B | 10,114.51% | ๐บ๐ธ USA |